Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$129.04 USD
+4.79 (3.86%)
Updated Apr 25, 2024 02:12 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Sarepta Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,243 | 933 | 702 | 540 | 381 |
Cost Of Goods | 150 | 140 | 97 | 63 | 57 |
Gross Profit | 1,093 | 793 | 605 | 477 | 324 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,361 | 1,329 | 1,065 | 1,041 | 1,030 |
Income After Depreciation & Amortization | -268 | -536 | -460 | -564 | -706 |
Non-Operating Income | -252 | -154 | 41 | 11 | -8 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -520 | -690 | -419 | -553 | -714 |
Income Taxes | 16 | 14 | 0 | 1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -536 | -703 | -419 | -554 | -715 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -536 | -703 | -419 | -554 | -715 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -270 | -494 | -422 | -539 | -683 |
Depreciation & Amortization (Cash Flow) | -2 | 42 | 38 | 25 | 22 |
Income After Depreciation & Amortization | -268 | -536 | -460 | -564 | -706 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 92.40 | 87.56 | 81.26 | 77.96 | 73.62 |
Diluted EPS Before Non-Recurring Items | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 |
Diluted Net EPS (GAAP) | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 |
Fiscal Year end for Sarepta Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 396.78 | 331.82 | 261.24 | 253.50 |
Cost Of Goods | NA | 44.18 | 37.03 | 34.12 | 35.02 |
Gross Profit | NA | 352.61 | 294.79 | 227.11 | 218.48 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 327.98 | 315.63 | 360.63 | 356.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 24.63 | -20.84 | -133.52 | -138.09 |
Non-Operating Income | NA | -86.25 | -12.33 | 118.93 | -374.62 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 40.37 | -33.17 | -14.59 | -512.71 |
Income Taxes | NA | -5.28 | 7.76 | 9.36 | 4.05 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 45.65 | -40.94 | -23.94 | -516.76 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 45.65 | -40.94 | -23.94 | -516.76 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 105.59 | 88.89 | 88.74 | 88.19 |
Diluted EPS Before Non-Recurring Items | NA | 0.47 | -0.46 | -0.27 | -1.44 |
Diluted Net EPS (GAAP) | NA | 0.79 | -0.46 | -0.27 | -5.86 |